CEO Pay Packages Expand in India But Ratio To Employee Earnings Hurts
Executive Summary
Top executives at leading local and foreign drug firms in India by and large earned more in 2020-21, while differentials in CEO to median employee remuneration remained stark. With increasing scrutiny by shareholders and lawmakers, experts suggest that pharma should be more mindful of balancing “adequate” C-suite compensation and glaring inequalities.
You may also be interested in...
J&J CEO Gorsky Handing Over The Reins To Vice Chairman Duato
Duato has been involved for the last several years in growing J&J’s pharma and consumer businesses and has led the company’s COVID-19 efforts. Gorsky is stepping down due to a family health issue.
CEO Pay In India: A Mixed Bag But Multiples Versus Employee Earnings Huge
Managing directors/CEOs of foreign firms in India drew higher remuneration in 2019-20 versus the previous year and overall earnings of peers at Indian firms continued to be way higher in general. CEO-to-employee pay ratios remains stark, reaching over 550 in one case.
Evotec, Takeda Execs’ Big Picture Insights To Shape India’s R&D Push
Evotec's CEO and Takeda’s president of R&D provide insights around how India could shape its efforts to accelerate biopharma innovation. Backing the right technologies, fostering a culture to "stop losses" early on for projects that don't work and learning from China’s overhaul of its healthcare system were among the key takeaways.